VC Firm SR One Closes $600M Fund to Build ‘Elite Biotechnology Companies’
SR One’s new investment fund is its second one since spinning out of GSK in 2020. The firm says it now has more than $1.5 billion in assets under management.
Morphic raises $80M in Series B round to fund oral integrin inhibitor development
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
GSK venture arm makes first health IT investment to speed up specialty pharma orders
Health IT startup ZappRx has raised $1 million as part of a pivot from its e-prescribing platform to focus on automating the cumbersome manual process of ordering specialty pharmaceuticals. ZappRx wants to shorten to a few days a process that can take up to 10 days and accounts for a disproportionate amount of pharmaceutical costs, according […]